Cosmo Pharmaceuticals CEO Giovanni Di Napoli discusses the challenges posed by androgenetic alopecia (AGA) and the potential impact of a clascoterone 5% topical solution based on new Phase 3 data.
advertisement
Promising New Data on Clascoterone for Androgenetic Alopecia
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Cosmo Pharmaceuticals CEO Giovanni Di Napoli discusses the challenges posed by androgenetic alopecia (AGA) and the potential impact of a clascoterone 5% topical solution based on new Phase 3 data.
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?